Veritas Investment Management LLP lifted its position in shares of CVS Health Corporation (NYSE:CVS) by 14.3% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 660,923 shares of the pharmacy operator’s stock after buying an additional 82,637 shares during the quarter. CVS Health Corporation makes up 7.8% of Veritas Investment Management LLP’s holdings, making the stock its 6th largest holding. Veritas Investment Management LLP owned 0.06% of CVS Health Corporation worth $53,194,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Keel Point LLC lifted its stake in shares of CVS Health Corporation by 0.7% during the 1st quarter. Keel Point LLC now owns 3,296 shares of the pharmacy operator’s stock valued at $259,000 after buying an additional 22 shares in the last quarter. First City Capital Management Inc. lifted its stake in shares of CVS Health Corporation by 0.3% during the 1st quarter. First City Capital Management Inc. now owns 12,771 shares of the pharmacy operator’s stock valued at $1,003,000 after buying an additional 40 shares in the last quarter. Elefante Mark B lifted its stake in shares of CVS Health Corporation by 0.7% during the 2nd quarter. Elefante Mark B now owns 6,400 shares of the pharmacy operator’s stock valued at $515,000 after buying an additional 45 shares in the last quarter. Traynor Capital Management Inc. lifted its stake in shares of CVS Health Corporation by 1.3% during the 2nd quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock valued at $290,000 after buying an additional 48 shares in the last quarter. Finally, Sequoia Financial Advisors LLC lifted its stake in shares of CVS Health Corporation by 0.8% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock valued at $515,000 after buying an additional 53 shares in the last quarter. Institutional investors own 82.04% of the company’s stock.

In other CVS Health Corporation news, EVP Thomas M. Moriarty sold 90,267 shares of the company’s stock in a transaction dated Monday, September 11th. The shares were sold at an average price of $79.61, for a total value of $7,186,155.87. Following the transaction, the executive vice president now directly owns 70,102 shares in the company, valued at approximately $5,580,820.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Jonathan C. Roberts sold 85,743 shares of the company’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $83.14, for a total transaction of $7,128,673.02. Following the completion of the transaction, the chief operating officer now owns 119,555 shares in the company, valued at $9,939,802.70. The disclosure for this sale can be found here. Insiders sold a total of 714,125 shares of company stock worth $58,119,381 over the last 90 days. Insiders own 0.61% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Veritas Investment Management LLP Grows Position in CVS Health Corporation (CVS)” was published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark law. The correct version of this news story can be viewed at https://www.watchlistnews.com/veritas-investment-management-llp-grows-position-in-cvs-health-corporation-cvs/1713165.html.

CVS Health Corporation (NYSE CVS) opened at $70.68 on Friday. The company has a market cap of $71,598.27, a PE ratio of 12.38, a P/E/G ratio of 1.21 and a beta of 0.86. CVS Health Corporation has a fifty-two week low of $66.45 and a fifty-two week high of $84.72. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67.

CVS Health Corporation (NYSE:CVS) last issued its quarterly earnings results on Monday, November 6th. The pharmacy operator reported $1.50 EPS for the quarter, beating the consensus estimate of $1.49 by $0.01. The company had revenue of $46.18 billion for the quarter, compared to the consensus estimate of $46.17 billion. CVS Health Corporation had a net margin of 2.77% and a return on equity of 16.96%. The firm’s revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.64 EPS. equities analysts predict that CVS Health Corporation will post 5.9 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which was paid on Friday, November 3rd. Shareholders of record on Tuesday, October 24th were paid a $0.50 dividend. The ex-dividend date was Monday, October 23rd. This represents a $2.00 dividend on an annualized basis and a yield of 2.83%. CVS Health Corporation’s dividend payout ratio is currently 41.32%.

Several analysts have commented on the stock. Royal Bank Of Canada assumed coverage on shares of CVS Health Corporation in a research note on Tuesday, September 19th. They issued an “outperform” rating and a $95.00 price target on the stock. Jefferies Group LLC boosted their price target on shares of CVS Health Corporation from $82.00 to $86.00 and gave the stock a “hold” rating in a research note on Friday, September 15th. BidaskClub upgraded shares of CVS Health Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Needham & Company LLC reiterated a “hold” rating on shares of CVS Health Corporation in a research note on Sunday, September 10th. Finally, Wolfe Research cut shares of CVS Health Corporation from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $89.00 to $82.00 in a research note on Monday, August 14th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $85.82.

CVS Health Corporation Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.